{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-008575","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.058488+00:00","generated_at":"2026-05-16T06:57:26.395780+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vyome VT-1953 valuation: $455M rNPV, potential $1.086B after Phase 3","bullets":["Independent report values VT-1953 at $455M rNPV in H1 2026, growing to $1.086B post-Phase 3 in H1 2028.","No FDA-approved therapies for malignant fungating wounds; 56.5% probability of approval assumed.","Peak net sales imply $2.2B TAM in 2026, $2.8B by 2040; 30% market share modeled.","Pricing $20/gram ($9,125/month); Phase 3 starts Q3 2026, NDA and launch targeted Q4 2028.","Development costs to 2028 estimated at $10M; potential partners include BMS and Pierre Fabre."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-008575","json":"https://secwatch.observer/filing/0001213900-26-008575.json","markdown":"https://secwatch.observer/filing/0001213900-26-008575.md","text":"https://secwatch.observer/filing/0001213900-26-008575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000121390026008575/0001213900-26-008575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000121390026008575/ea0274367-8k_vyome.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:57:26.395780+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}